Assessment of user perspectives of cardiac point of care technologies in chest pain diagnosis

F FitzGibbon, A Brown, BJ Meenan

Research output: Chapter in Book/Report/Conference proceedingConference contribution

6 Citations (Scopus)

Abstract

The assessment of the value of point of caretechnologies for cardiac marker testing in patients presentingwith chest pain was carried out using an on-line survey tool togarner the views and opinions of healthcare professionals onpoint of care testing (POCT). The preliminary results of thesurvey are presented here. A total of 38 responses werereceived, from health care professionals within NorthernIreland Health Trusts. A number of concerns were raisedrelating to the implementation of a POCT service. Theseincluded clinical governance, quality assurance, accreditationand regulation, which should be addressed by the centrallaboratory.The main POCT user groups were clinical, nursing andlaboratory staff, with nursing staff being the most frequentusers. The general opinion amongst healthcare professionalswas that POCT implementation and accreditation should beoverseen and regulated by the central laboratory. Troponin Iwas the most important cardiac marker measured by POCTdevices. POCT turnaround times were perceived by surveyrespondents as shorter between 15-30 minutes compared tolaboratory testing, 60-90 minutes. The perception of POCT dataquality was considered by the majority of respondents to be ofequivalent quality and accuracy to central laboratory cardiacmarker testing Laboratory and biomedical scientists indicatedthat the implementation of a POCT service would alter theirrelationships to clinical, nursing staff and patients. The surveysuggested that POCT may create new roles for biomedicalscientists outside the pathology laboratory involving supportingnursing staff at ward level and validation of patient test results.
LanguageEnglish
Title of host publicationUnknown Host Publication
Pages1762-1765
Number of pages4
Publication statusPublished - 23 Aug 2007
Event29th Annual International Conference of the IEEE EMBS - Lyon, France
Duration: 23 Aug 2007 → …

Conference

Conference29th Annual International Conference of the IEEE EMBS
Period23/08/07 → …

Fingerprint

Point-of-Care Systems
Nursing Staff
Chest Pain
Delivery of Health Care
Clinical Governance
Laboratory Personnel
Troponin
Accreditation
Pathology
Health
Surveys and Questionnaires

Cite this

@inproceedings{8928382757204443b9b186f9286cf870,
title = "Assessment of user perspectives of cardiac point of care technologies in chest pain diagnosis",
abstract = "The assessment of the value of point of caretechnologies for cardiac marker testing in patients presentingwith chest pain was carried out using an on-line survey tool togarner the views and opinions of healthcare professionals onpoint of care testing (POCT). The preliminary results of thesurvey are presented here. A total of 38 responses werereceived, from health care professionals within NorthernIreland Health Trusts. A number of concerns were raisedrelating to the implementation of a POCT service. Theseincluded clinical governance, quality assurance, accreditationand regulation, which should be addressed by the centrallaboratory.The main POCT user groups were clinical, nursing andlaboratory staff, with nursing staff being the most frequentusers. The general opinion amongst healthcare professionalswas that POCT implementation and accreditation should beoverseen and regulated by the central laboratory. Troponin Iwas the most important cardiac marker measured by POCTdevices. POCT turnaround times were perceived by surveyrespondents as shorter between 15-30 minutes compared tolaboratory testing, 60-90 minutes. The perception of POCT dataquality was considered by the majority of respondents to be ofequivalent quality and accuracy to central laboratory cardiacmarker testing Laboratory and biomedical scientists indicatedthat the implementation of a POCT service would alter theirrelationships to clinical, nursing staff and patients. The surveysuggested that POCT may create new roles for biomedicalscientists outside the pathology laboratory involving supportingnursing staff at ward level and validation of patient test results.",
author = "F FitzGibbon and A Brown and BJ Meenan",
note = "Reference text: [1] K. Rajappan, E. Murphy, V. Amber, F. Meakin, B. Muller, K. F. Fox and C. S. R. Baker, {"}Usage of Troponin in the Real World: A Lesson for the Introduction of Biochemical Assays.{"} Q J Med, vol. 98, pp. 337-342, 2005. 2005. [2] R. Luengo-Fernandez, J. Leal, A. Gray, S. Petersen and M. Rayner, {"}Cost of Cardiovascular Diseases in the United Kingdom.{"} Heart, vol. 92, pp. 1384-1389, 2006. 2006. [3] T. Ali, J. Scrafton and R. Andrews, {"}Near-Patient Testing for cardiac Troponin I to Reduce Hospital Stay in Patients Presenting with Chest pain.{"} Br J Cardiol (Acute Interv Cardiol), vol. 13, pp. 19-21, 2006. 2006. [4] J. P. Dougan, T. P. Mathew, J. W. Riddell, M. S. Spence, G. S. McGlinchey, M. Nesbitt, M. Smye, I. B. A. Menown and A. A. J. Adgey, {"}Suspected Angina Pectoris: A rapid-Access Chest Pain Clinic.{"} Q J Med, vol. 94, pp. 679-686, 2001. 2001. [5] S. Goodacre, T. Locker, J. Arnold, K. Angelini and F. Morris, {"}Which Diagnostic Test are Most useful in a Chest Pain Unit protocol?{"} BMC Emerg Med, vol. 5, pp. 1-7, 2005. 2005. [6] R. G. Males, J. Stephenson and P. Harris, {"}Cardiac Markers and Point of Care Testing: A Perfect Fit.{"} Crit Care Nurs Q, vol. 24, pp. 54-61, 2001. 2001. [7] C. P. Price, {"}Point of Care Testing,{"} BMJ, vol. 322, pp. 1285-1288, 2001. 2001. [8] J. K. Kost and N. K. Tran, {"}Point of Care Testing and Cardiac Biomarkers: The Standard of Care and Vision for Chest Pain Centers,{"} Cardiol Clin, vol. 23, pp. 467-490, 2005. 2005. [9] C. P. Price, {"}Medical and Economic Outcomes of Point of Care Testing.{"} Clin Chem Lab Med, vol. 40, pp. 246-251, 2002. 2002. [10] {"}The future of pathology services in Northern Ireland. Department of Health, Social Services and Public Safety.{"} Central Print Unit, Department of Health, Social Services & Public Safety, Belfast, Tech. Rep. 169/2006, Nov 2006, 2006. [11] B. Conway, J. O'Connor and B. McClements, {"}Impact of Serum Troponin Measurement on Triage of Chest Pain in a District Hospital,{"} Ulst Med J, vol. 72, pp. 86-92, 2003. 2003. [12] J. K. Kost, S. S. Ehrmeyer, B. Chernow, J. W. Winklemann, G. P. Zaloga, R. P. Dellinger and T. Shirey, {"}The Laboratory-Clinical Interface. Point-of-Care Testing.{"} Chest, vol. 115, pp. 1140-1154, 1999. 1999. [13] R. Bauer, L. Cherynk, T. Thompson and D. Whitehair, {"}Stratus CS Stat Fluorometric Analyzer.{"} Point of Care, vol. 1, pp. 54-57, 2002. 2002. [14] K. M. Eggers, J. Oldgren, A. Nordenskjold and B. Lindahl, {"}Diagnostic Value of Serial Measurement of Cardiac markers in Patients with Chest Pain: Limited Value of adding Myoglobin to Troponin I for Exclusion of Myocardial Infarction.{"} Am Heart J, vol. 148, pp. 574-581, 2004. 2004. [15] P. O. Collinson, C. John, S. Lynch, A. Rao, R. Canepa-Anson, E. Carson and D. Cramp, {"}A prospective randomised Controlled Trial of Point of care Testing on the Coronary Care Unit.{"} Ann Clin Biochem, vol. 41, pp. 397-404, 2004. 2004. [16] F. Di Serio, R. Lovero, M. Leone, R. De Sario, V. Ruggieri, L. Varrasco and N. Parsini, {"}Integration Between the Tele-Cardiology Unit and the Central Laboratory: Methodological and Clinical Evaluation of Point of Care Testing cardiac marker in the Ambulance.{"} Clin Chem Lab Med, vol. 44, pp. 768-773, 2006. 2006. [17] B. Beneteau-Burnat, B. Baudin and M. Vaubourdolle, {"}Evaluation of Stratus CS Stat Fluorimetric Analyser for Measurement of Cardiac Markers Troponin I (cTnI), Creatine Kinase MB (CK-MB) and Myoglobin.{"} J Clin Lab Anal, vol. 15, pp. 314-318, 2001. 2001. [18] F. S. Apple, M. A. Murakami, R. H. Christenson, J. L. Campbell, C. J. Miller, K. G. Hock and M. G. Scott, {"}Analytical Performance of the i-Stat Cardiac Troponin I Assay.{"} Clin Chim Acta, vol. 345, pp. 123-127, 2004. 2004. [19] S. Ming Ng, P. Krishnaswamy, R. Morissey, P. Clopton, R. Fitzgerald and A. S. Maisel, {"}Ninety Minute Accelerated Critical Pathway for Chest Pain Evaluation.{"} Am J Cardiol, vol. 88, pp. 611-617, 2001. 2001. [20] G. M. Creed, {"}Point of Care Testing in the United Kingdom.{"} Crit Care Nurs Q, vol. 24, pp. 44-48, 2001. 2001. [21] {"}Report on the review of NHS pathology services in England and Wales. Department of Health.{"} Tech. Rep. 27515, Aug 2006, 2006. [22] J. Pearson, {"}Point of Care Testing and Clinical Governance,{"} Clin Chem Lab Med, vol. 44, pp. 765-767, 2006. 2006.",
year = "2007",
month = "8",
day = "23",
language = "English",
pages = "1762--1765",
booktitle = "Unknown Host Publication",

}

FitzGibbon, F, Brown, A & Meenan, BJ 2007, Assessment of user perspectives of cardiac point of care technologies in chest pain diagnosis. in Unknown Host Publication. pp. 1762-1765, 29th Annual International Conference of the IEEE EMBS, 23/08/07.

Assessment of user perspectives of cardiac point of care technologies in chest pain diagnosis. / FitzGibbon, F; Brown, A; Meenan, BJ.

Unknown Host Publication. 2007. p. 1762-1765.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Assessment of user perspectives of cardiac point of care technologies in chest pain diagnosis

AU - FitzGibbon, F

AU - Brown, A

AU - Meenan, BJ

N1 - Reference text: [1] K. Rajappan, E. Murphy, V. Amber, F. Meakin, B. Muller, K. F. Fox and C. S. R. Baker, "Usage of Troponin in the Real World: A Lesson for the Introduction of Biochemical Assays." Q J Med, vol. 98, pp. 337-342, 2005. 2005. [2] R. Luengo-Fernandez, J. Leal, A. Gray, S. Petersen and M. Rayner, "Cost of Cardiovascular Diseases in the United Kingdom." Heart, vol. 92, pp. 1384-1389, 2006. 2006. [3] T. Ali, J. Scrafton and R. Andrews, "Near-Patient Testing for cardiac Troponin I to Reduce Hospital Stay in Patients Presenting with Chest pain." Br J Cardiol (Acute Interv Cardiol), vol. 13, pp. 19-21, 2006. 2006. [4] J. P. Dougan, T. P. Mathew, J. W. Riddell, M. S. Spence, G. S. McGlinchey, M. Nesbitt, M. Smye, I. B. A. Menown and A. A. J. Adgey, "Suspected Angina Pectoris: A rapid-Access Chest Pain Clinic." Q J Med, vol. 94, pp. 679-686, 2001. 2001. [5] S. Goodacre, T. Locker, J. Arnold, K. Angelini and F. Morris, "Which Diagnostic Test are Most useful in a Chest Pain Unit protocol?" BMC Emerg Med, vol. 5, pp. 1-7, 2005. 2005. [6] R. G. Males, J. Stephenson and P. Harris, "Cardiac Markers and Point of Care Testing: A Perfect Fit." Crit Care Nurs Q, vol. 24, pp. 54-61, 2001. 2001. [7] C. P. Price, "Point of Care Testing," BMJ, vol. 322, pp. 1285-1288, 2001. 2001. [8] J. K. Kost and N. K. Tran, "Point of Care Testing and Cardiac Biomarkers: The Standard of Care and Vision for Chest Pain Centers," Cardiol Clin, vol. 23, pp. 467-490, 2005. 2005. [9] C. P. Price, "Medical and Economic Outcomes of Point of Care Testing." Clin Chem Lab Med, vol. 40, pp. 246-251, 2002. 2002. [10] "The future of pathology services in Northern Ireland. Department of Health, Social Services and Public Safety." Central Print Unit, Department of Health, Social Services & Public Safety, Belfast, Tech. Rep. 169/2006, Nov 2006, 2006. [11] B. Conway, J. O'Connor and B. McClements, "Impact of Serum Troponin Measurement on Triage of Chest Pain in a District Hospital," Ulst Med J, vol. 72, pp. 86-92, 2003. 2003. [12] J. K. Kost, S. S. Ehrmeyer, B. Chernow, J. W. Winklemann, G. P. Zaloga, R. P. Dellinger and T. Shirey, "The Laboratory-Clinical Interface. Point-of-Care Testing." Chest, vol. 115, pp. 1140-1154, 1999. 1999. [13] R. Bauer, L. Cherynk, T. Thompson and D. Whitehair, "Stratus CS Stat Fluorometric Analyzer." Point of Care, vol. 1, pp. 54-57, 2002. 2002. [14] K. M. Eggers, J. Oldgren, A. Nordenskjold and B. Lindahl, "Diagnostic Value of Serial Measurement of Cardiac markers in Patients with Chest Pain: Limited Value of adding Myoglobin to Troponin I for Exclusion of Myocardial Infarction." Am Heart J, vol. 148, pp. 574-581, 2004. 2004. [15] P. O. Collinson, C. John, S. Lynch, A. Rao, R. Canepa-Anson, E. Carson and D. Cramp, "A prospective randomised Controlled Trial of Point of care Testing on the Coronary Care Unit." Ann Clin Biochem, vol. 41, pp. 397-404, 2004. 2004. [16] F. Di Serio, R. Lovero, M. Leone, R. De Sario, V. Ruggieri, L. Varrasco and N. Parsini, "Integration Between the Tele-Cardiology Unit and the Central Laboratory: Methodological and Clinical Evaluation of Point of Care Testing cardiac marker in the Ambulance." Clin Chem Lab Med, vol. 44, pp. 768-773, 2006. 2006. [17] B. Beneteau-Burnat, B. Baudin and M. Vaubourdolle, "Evaluation of Stratus CS Stat Fluorimetric Analyser for Measurement of Cardiac Markers Troponin I (cTnI), Creatine Kinase MB (CK-MB) and Myoglobin." J Clin Lab Anal, vol. 15, pp. 314-318, 2001. 2001. [18] F. S. Apple, M. A. Murakami, R. H. Christenson, J. L. Campbell, C. J. Miller, K. G. Hock and M. G. Scott, "Analytical Performance of the i-Stat Cardiac Troponin I Assay." Clin Chim Acta, vol. 345, pp. 123-127, 2004. 2004. [19] S. Ming Ng, P. Krishnaswamy, R. Morissey, P. Clopton, R. Fitzgerald and A. S. Maisel, "Ninety Minute Accelerated Critical Pathway for Chest Pain Evaluation." Am J Cardiol, vol. 88, pp. 611-617, 2001. 2001. [20] G. M. Creed, "Point of Care Testing in the United Kingdom." Crit Care Nurs Q, vol. 24, pp. 44-48, 2001. 2001. [21] "Report on the review of NHS pathology services in England and Wales. Department of Health." Tech. Rep. 27515, Aug 2006, 2006. [22] J. Pearson, "Point of Care Testing and Clinical Governance," Clin Chem Lab Med, vol. 44, pp. 765-767, 2006. 2006.

PY - 2007/8/23

Y1 - 2007/8/23

N2 - The assessment of the value of point of caretechnologies for cardiac marker testing in patients presentingwith chest pain was carried out using an on-line survey tool togarner the views and opinions of healthcare professionals onpoint of care testing (POCT). The preliminary results of thesurvey are presented here. A total of 38 responses werereceived, from health care professionals within NorthernIreland Health Trusts. A number of concerns were raisedrelating to the implementation of a POCT service. Theseincluded clinical governance, quality assurance, accreditationand regulation, which should be addressed by the centrallaboratory.The main POCT user groups were clinical, nursing andlaboratory staff, with nursing staff being the most frequentusers. The general opinion amongst healthcare professionalswas that POCT implementation and accreditation should beoverseen and regulated by the central laboratory. Troponin Iwas the most important cardiac marker measured by POCTdevices. POCT turnaround times were perceived by surveyrespondents as shorter between 15-30 minutes compared tolaboratory testing, 60-90 minutes. The perception of POCT dataquality was considered by the majority of respondents to be ofequivalent quality and accuracy to central laboratory cardiacmarker testing Laboratory and biomedical scientists indicatedthat the implementation of a POCT service would alter theirrelationships to clinical, nursing staff and patients. The surveysuggested that POCT may create new roles for biomedicalscientists outside the pathology laboratory involving supportingnursing staff at ward level and validation of patient test results.

AB - The assessment of the value of point of caretechnologies for cardiac marker testing in patients presentingwith chest pain was carried out using an on-line survey tool togarner the views and opinions of healthcare professionals onpoint of care testing (POCT). The preliminary results of thesurvey are presented here. A total of 38 responses werereceived, from health care professionals within NorthernIreland Health Trusts. A number of concerns were raisedrelating to the implementation of a POCT service. Theseincluded clinical governance, quality assurance, accreditationand regulation, which should be addressed by the centrallaboratory.The main POCT user groups were clinical, nursing andlaboratory staff, with nursing staff being the most frequentusers. The general opinion amongst healthcare professionalswas that POCT implementation and accreditation should beoverseen and regulated by the central laboratory. Troponin Iwas the most important cardiac marker measured by POCTdevices. POCT turnaround times were perceived by surveyrespondents as shorter between 15-30 minutes compared tolaboratory testing, 60-90 minutes. The perception of POCT dataquality was considered by the majority of respondents to be ofequivalent quality and accuracy to central laboratory cardiacmarker testing Laboratory and biomedical scientists indicatedthat the implementation of a POCT service would alter theirrelationships to clinical, nursing staff and patients. The surveysuggested that POCT may create new roles for biomedicalscientists outside the pathology laboratory involving supportingnursing staff at ward level and validation of patient test results.

M3 - Conference contribution

SP - 1762

EP - 1765

BT - Unknown Host Publication

ER -